Axonics® Responds to Patent Action by Medtronic
IRVINE, Calif.--(BUSINESS WIRE)--Nov 5, 2019--
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing sacral neuromodulation (“SNM”) devices, today announced that it received notice on Monday, November 4, that Medtronic, Inc, Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and its U.S. operating company Medtronic USA, Inc. (“Medtronic”) filed a lawsuit against Axonics in the United States District Court for the Central District of California. The lawsuit asserts that the Axonics r-SNM® System infringes Medtronic’s U.S. Patent Nos. 8,036,756, 8,626,314, 9,463,324, and 9,821,112. The lawsuit requests the typical remedies for patent infringement, including damages and an injunction.
Axonics has invested substantial time and resources in understanding the competitive landscape over the years since its inception in October 2013 and has been careful to respect the intellectual property rights of others in the design of its products, including the rights of Medtronic. Axonics is prepared to act quickly and defend itself aggressively and has already begun working with legal counsel. Beyond this, the need to protect the confidentiality of attorney communications limits what the Company can say about the specific allegations at this time.
“Axonics believes that this lawsuit is the kind of response that is all too predictable from Medtronic signaling that it is lacking the wherewithal to compete fairly. It is ironic that the largest medical device company in the world, with over a 20-year long monopoly in the SNM market, failed to introduce any meaningful innovation for the sake of patients or their physician customers. Instead, they have chosen to employ legal tactics to engage in clear anticompetitive behavior and yet another attempt to change the dialogue with physicians and U.S. institutional investors,” said Axonics CEO Raymond W. Cohen.
Cohen continued, “We believe in competition. Our team is neither naive, nor inexperienced and we refuse to be intimidated. We have developed our own considerable IP estate relating to our technology platform. It should be obvious, to even the most casual observer, that this is an attempt to use legal tactics to slow down competition, and deny patients and physicians the innovative new technology that they desire. The bottom line is that a large number of Medtronic’s customers want to work with Axonics and offer their patients our long-lived, fuss free, full-body MRI-capable SNM system, and we will continue to work vigorously to accomplish our objective of becoming the market leader in SNM.”
About Axonics Modulation Technologies, Inc. and Sacral Neuromodulation
Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. The Axonics r-SNM System is the first rechargeable SNM system approved for sale in the United States, Europe, Canada and Australia. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics r-SNM System is also the first SNM system to gain full-body MRI conditional labeling. For more information, visit the Company’s website at www.axonicsmodulation.com.
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191105005415/en/
CONTACT: Axonics’ Contact
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
email@example.comInvestor & Media Contact
Matt Clawson, +1-949-370-8500
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH
SOURCE: Axonics Modulation Technologies, Inc.
Copyright Business Wire 2019.
PUB: 11/05/2019 06:00 AM/DISC: 11/05/2019 06:01 AM